Unsplash+Swedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. Voima Ventures and Nordic Science Investments led the private financing. Illumina Ventures, Almi Invest, Life Science Invest and several genomics-focused private investors also participated.
Tag Archive for: funding
QLi5 Therapeutics has completed a €6.26 million capital increase led by its Korean co-founder, Qurient, which has also increased its voting stake in the German biotech. The funding will be used to advance QLi5’s proteasome inhibitor(PI)-based antibody-drug conjugate (ADC) payload platform, an approach the company is presenting as a next step beyond today’s dominant ADC payload classes.
bit.bio has raised $50 million in a series C round led by M&G Investments to support the next phase of its human cell programming business. The Cambridge-based company develops defined human cells using its opti-ox technology, supplying reproducible cell types to researchers and drug developers for use in drug discovery.
adobe stock photos - Wang Dan French biotech Ciloa SAS has received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, ahead of efficacy evaluation in indications including type 2 diabetes, obesity, and liver fibrosis.
Bild von freepikDutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.
APEIRON/invIOsAustria has once again come a little closer to its goal of achieving the highest research and development rate (R&D rate) in the EU. Two thirds of R&D investments are made by industry, of which around 16% are made by foreign companies. Two current examples of investments in Austria from the life sciences sector are Novartis and Ligand Pharmaceuticals.
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.